The eIF5A hypusination inhibitor GC7 (N1-guanyl-1,7-diaminoheptane) was shown to protect from ischemic
injuries. We hypothesized that GC7 could be useful for preconditioning kidneys from donors before
transplantation. Using a preclinical porcine
brain death (BD) donation model, we carried out in vivo evaluation of GC7 pretreatment (3 mg/kg iv, 5 minutes after BD) at the beginning of the 4h-donor management, after which kidneys were collected and cold-stored (18h in University of Wisconsin
solution) and 1 was allotransplanted. Groups were defined as following (n = 6 per group): healthy (CTL), untreated BD (Vehicle), and GC7-treated BD (Vehicle + GC7). At the end of 4h-management, GC7 treatment decreased BD-induced markers, as
radical oxygen species markers. In addition, GC7 increased expression of mitochondrial protective
peroxisome proliferator-activated receptor-gamma coactivator-1-alpha (PGC1α) and
antioxidant proteins (superoxyde-dismutase-2,
heme oxygenase-1, nuclear factor [erythroid-derived 2]-like 2 [NRF2], and
sirtuins). At the end of cold storage, GC7 treatment induced an increase of NRF2 and PGC1α
mRNA and a better mitochondrial integrity/homeostasis with a decrease of
dynamin- related protein-1 activation and increase of mitofusin-2. Moreover, GC7 treatment significantly improved kidney outcome during 90 days follow-up after
transplantation (fewer creatininemia and
fibrosis). Overall, GC7 treatment was shown to be protective for kidneys against BD-induced
injuries during donor management and subsequently appeared to preserve
antioxidant defenses and mitochondria homeostasis; these protective effects being accompanied by a better
transplantation outcome.